A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs GDC 0853 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 07 Jun 2017 Biomarkers information updated
- 03 Apr 2017 Status changed from active, no longer recruiting to recruiting.
- 29 Mar 2017 Planned End Date changed from 1 Oct 2019 to 24 Jul 2019.